[{"orgOrder":0,"company":"NodThera","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"NT-0167","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"NodThera","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Organovo Holdings"},{"orgOrder":0,"company":"NodThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NodThera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Undisclosed"},{"orgOrder":0,"company":"NodThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NodThera \/ Undisclosed"},{"orgOrder":0,"company":"NodThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Undisclosed"},{"orgOrder":0,"company":"NodThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Endocrinology","graph2":"Phase II","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NodThera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NodThera \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by NodThera

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : NT-0796 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity-associated with Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 09, 2025

                          Lead Product(s) : NT-0796

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : NT-0796 is an oral, brain-penetrant NLRP3 inflammasome inhibitor, being investigated on inflammation in obese participants at risk of cardiovascular disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 12, 2024

                          Lead Product(s) : NT-0796

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : NT-0796 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cardiovascular Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 13, 2023

                          Lead Product(s) : NT-0796

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : NT-0796 is a novel chemotype, designed as an orally bioavailable, brain penetrant NLRP3 inhibitor. NT-0796 has completed its Phase 1 study confirming brain penetration with excellent pharmacokinetic (PK) & pharmacodynamic (PD) profiles.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 21, 2022

                          Lead Product(s) : NT-0796

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          June 03, 2020

                          Lead Product(s) : NT-0167

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Organovo Holdings

                          Deal Size : $55.0 million

                          Deal Type : Series B Financing

                          blank